MARAVAI LIFESCIENCES HOLDINGS, INC.

Maravai LifeSciences Holdings, Inc. is a life sciences company that provides essential products and services for developing drugs, therapeutics, vaccines, and diagnostics, as well as supporting human disease research. Its customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions, and diagnostics companies. The company offers complex nucleic acids for therapeutic, vaccine, and diagnostic applications; custom enzymes for research and diagnostic use; and antibody-based solutions for detecting impurities during biopharmaceutical production. Maravai operates in two business segments: TriLink and Cygnus. These segments were renamed during fiscal year 2025 from Nucleic Acid Production and Biologics Safety Testing, respectively, to align with internal brand and operating terminology, with no changes to their composition or offerings. TriLink, which accounted for 64% of revenue for the year ended December 31, 2025, is a global provider of highly modified, complex nucleic acids and related products. Its core offerings include mRNA, proprietary CleanCap® mRNA capping and ModTail™ poly(A) tail modification technologies, long and short oligonucleotides, oligonucleotide inputs, nucleoside triphosphates, custom nucleic chemistry, and specialty enzymes. Cygnus provides biologics safety testing products and services, including host cell protein ELISA kits, impurity detection assays, viral clearance prediction tools, ancillary reagents, and custom analytical services.